一项元分析确定了驱动基因,并描述了结直肠癌的分子流行病学
Sigurgeir Olafsson1, Thorri Thorarinsson2, Sigurjon A Gudjonsson2
1Amgen deCODE Genetics, Reykjavik, Iceland. sigurgeo@decode.is.
Scientific reports
|February 17, 2026
概括
结合来自11000多名结直肠癌患者的数据,揭示了推动癌症发展的关键基因突变. 这次元分析确定了112个正在选择中的基因和57个具有相互依赖突变的基因对.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 生物信息学是一种生物信息学.
背景情况:
- 结肠直肠癌 (CRC) 的发病过程涉及体质突变的逐步积累.
- 对CRC分子驱动因素的个别研究往往受样本大小的限制.
- 结合来自多项研究的数据可以增强统计能力,并揭示新的见解.
研究的目的:
- 将来自冰岛CRC患者的向测序数据与公开可用的数据集集集成.
- 在积极选择下识别基因,并了解CRC发育中的基因相互作用.
- 探索分子变化和瘤表型之间的关联.
主要方法:
- 针对2172个冰岛结肠直肠癌的目标测序.
- 后分析将这些数据与文学中的9515个额外的瘤结合起来.
- 对微卫星稳定 (MSS) 和微卫星不稳定 (MSI) 瘤的单独分析.
- 条件选择分析以确定基因对相互作用.
主要成果:
- 在多项研究和多种不同的人口统计数据中,确定了112个基因突变的积极选择.
- 发现了57对具有条件选择证据的基因对,表明相互依赖的突变模式.
- 在MSS瘤中发现了粘膜组织学与转化生长因子β (TGFb) 途径的突变之间的显著关联.
结论:
- 结合多个来源的基因组数据,大大提高了对结直肠癌驱动因素的理解.
- 该研究强调了特定的基因和途径,这些基因和途径对CRC发育和进展至关重要.
- 大规模数据集的整合使得癌症中基因型-表型相关性的稳健识别成为可能.
相关概念视频
01:29Pharmacogenomics: Identification of New Drug Targets
20
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
20
01:11Genome-wide Association Studies-GWAS
15.8K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.8K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
24
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
24